

# Global Life Sciences Fund A2 USD

Janus Henderson  
INVESTORS

**Fund facts at 31 May 2023** **Date of issue: 14 June 2023**

## Structure

Irish Investment Company

## Fund launch date

31 March 2000

## Share class launch date

31 March 2000

## Base currency

USD

## Fund size (USD)

3.72bn

## Benchmark

MSCI World Health Care

## Fund managers

Andy Acker, CFA

Daniel Lyons, Ph.D., CFA

## Minimum investment (USD)

2,500

## NAV (USD)

47.74

## Maximum initial charge

5.00%

## Annual management charge (AMC)

1.50% pa

## Total expense ratio

2.39%

## Codes

ISIN: IE0009355771

Sedol: 0935577

Bloomberg: JANGLA1 ID

Valor: 1060639

WKN: 935590

## Ratings

Morningstar - ★★★★★

## Objective and investment policy

The Fund aims to provide capital growth over the long term.

The Fund invests at least 80% of its assets in shares (also known as equities) selected for their growth potential and with a life sciences orientation. The Fund may invest in companies of any size, in any country.

## Additional information

From 31 January 2023, Daniel Lyons Ph.D., CFA also manages the fund. The MSCI World Healthcare index is a reference benchmark for performance reporting only.

Information relating to other currencies and fee structure can be found in the fund prospectus.

Refer to Annual Report and Accounts for more information on fees and expenses, AMC included.

## Performance in (USD)

Percentage growth, 31 May 2018 to 31 May 2023.



■ Janus Henderson Global Life Sciences Fund A2 USD (49.5%)

■ MSCI World Health Care NR (58.4%)

Annualised performance %	A2	A2 (with sales charge) <sup>^</sup>	Benchmark
1 month	-2.5	-7.3	-4.1
3 months	3.9	-1.3	2.5
6 months	-1.4	-6.3	-3.5
YTD	-0.4	-5.4	-2.3
1 year	9.4	3.9	-0.3
3 years (p.a)	6.5	4.7	6.9
5 years (p.a)	8.4	7.3	9.6
10 years (p.a)	11.2	10.7	9.9
Since inception 31 Mar 2000 (p.a)	7.0	6.7	7.5

Source: at 31 May 2023. © 2023 Morningstar. All rights reserved, performance is net of fees, with gross income reinvested. Performance figures of less than 1 year are not annualized.

The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

**Past performance is not a guide to future performance.**

# Global Life Sciences Fund A2 USD

Janus Henderson  
INVESTORS

Top 10 holdings	(%)	Industry breakdown	(%)	Market capitalisation	(%)
UnitedHealth Group Inc	6.3	Biotechnology	31.4	Over \$100B	45.1
AstraZeneca PLC	4.4	Pharmaceuticals	31.3	\$50B to \$100B	10.7
Eli Lilly & Co	3.5	Health Care Equipment	14.2	\$10B to \$50B	18.4
Merck & Co Inc	2.9	Managed Health Care	11.1	\$5B to \$10B	6.8
Sanofi	2.8	Life Sciences Tools & Services	6.1	\$1B to \$5B	14.0
Abbott Laboratories	2.6	Health Care Supplies	2.4	\$500M to \$1B	2.4
AbbVie Inc	2.4	Health Care Services	1.3	\$250M to \$500M	0.2
Novartis AG (ADR)	2.4	Health Care Distributors	1.3	Under \$100M	0.0
Sarepta Therapeutics Inc	2.4	Health Care Facilities	0.5	N/A	2.2
Thermo Fisher Scientific Inc	2.3	Application Software	0.1		
<b>Total number of positions</b>	<b>131</b>				

## What are the risks specific to this fund?

- When the Fund, or a share/unit class, seeks to mitigate exchange rate movements of a currency relative to the base currency (hedge), the hedging strategy itself may positively or negatively impact the value of the Fund due to differences in short-term interest rates between the currencies.
- The Fund could lose money if a counterparty with which the Fund trades becomes unwilling or unable to meet its obligations, or as a result of failure or delay in operational processes or the failure of a third party provider.
- Shares/Units can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
- Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses.
- If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified.
- The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events.
- The Fund may use derivatives to help achieve its investment objective. This can result in leverage (higher levels of debt), which can magnify an investment outcome. Gains or losses to the Fund may therefore be greater than the cost of the derivative. Derivatives also introduce other risks, in particular, that a derivative counterparty may not meet its contractual obligations.
- If the Fund holds assets in currencies other than the base currency of the Fund, or you invest in a share/unit class of a different currency to the Fund (unless hedged, i.e. mitigated by taking an offsetting position in a related security), the value of your investment may be impacted by changes in exchange rates.
- Securities within the Fund could become hard to value or to sell at a desired time and price, especially in extreme market conditions when asset prices may be falling, increasing the risk of investment losses.

## General risks

- Past performance is not a guide to future performance.
- The value of an investment and income can fall as well as rise and you may not get back the amount originally invested.
- Tax assumptions and reliefs depend upon an investor's particular circumstances and may be subject to change.

For further information please visit our website at [www.janushenderson.com/sg](http://www.janushenderson.com/sg)

# Global Life Sciences Fund A2 USD

Janus Henderson  
INVESTORS

## Important information

**ESG integration is the practice of incorporating material environmental, social and governance (ESG) information or insights in a non-binding manner alongside traditional measures into the investment decision process to improve long term financial outcomes of portfolios. This product does not pursue a sustainable investment strategy or have a sustainable investment objective or otherwise take ESG factors into account in a binding manner. ESG related research is one of many factors considered within the investment process and in this material we seek to show why it is financially relevant.**

<sup>^</sup>Performance with sales charge assume 5.00% initial sales charge/front-end load (FEL) applied. All ongoing charges stated are as per latest published report and accounts. Where the ongoing charges exceed the target outperformance relative to the benchmark the return is likely to be below the benchmark return, even when the Fund's outperformance target (before the deduction of charges) has been achieved. For funds which charge performance fees, investors should note that the total expense ratio includes the performance fees crystallised for the preceding performance period. Please note: due to rounding the figures in the holdings breakdowns may not add up to 100%.

Issued in Singapore by Janus Henderson Investors (Singapore) Limited, licensed and regulated by the Monetary Authority of Singapore, Company Registration No. 199700782N. **This advertisement has not been reviewed by the Monetary Authority of Singapore.**

The content herein is produced for information purposes only and does not constitute investment advice or as an offer to sell, buy or a recommendation for any security. Janus Henderson Investors is not responsible for any unlawful distribution of this document to any third parties, in whole or in part, and do not make any warranties with regards to the results obtained from its use. In preparing this document, Janus Henderson Investors has reasonable belief to rely upon the accuracy and completeness of all information available from public sources. **Past performance is no guarantee of future results. Investing involves risk, including the possible loss of principal and fluctuation of value.**

The Fund may employ investment techniques and instruments for investment purposes, such as trading in futures, options and swaps and other financial derivative instruments.

This document has been prepared by Janus Henderson Investors (Singapore) Limited, the Singapore Representative of the Fund. The Fund is distributed by authorised distributors. The prospectus and Product Highlights Sheet ("PHS") of the Fund are available and may be obtained from the Singapore Representative's office and the authorized distributors' offices. Investors should read the prospectus and PHS before deciding whether to invest in the shares of the Fund.

Investors are warned that they should only make their investments based on the most recent offering documents which contains information about fees, expenses and risks, which is available from appointed intermediaries, and which should be read carefully. An investment in the Fund may not be suitable for all investors and is not available to all investors in all jurisdictions; it is not available to US persons. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements. Shares, if redeemed, may be worth more or less than their original cost.

Investors are advised to consult your intermediary who will give you advice on the product suitability and help you determine how your investment would be consistent with your own investment objectives. The investment decisions are yours and an investment in the Fund may not be suitable for everyone. If in doubt, please contact your intermediary for clarification. Portfolio holdings are subject to change without notice.

2021 Morningstar. All Rights Reserved. CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute. Janus Henderson is a trademark of Janus Henderson Group plc or one of its subsidiary entities. ©Janus Henderson Group plc.